Local cardiac renin - Angiotensin system: Hypertension and cardiac failure

Journal of Molecular and Cellular Cardiology

Volumn 34, Issue 11, 2002, Pages 1435-1442

  Varagic, Jasmina ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Angiotensin; Diastolic dysfunction; Fibrosis; Heart failure; Hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; RENIN; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; CONFERENCE PAPER; DIASTOLE; ENDOCRINE SYSTEM; FIBROSIS; HEART FAILURE; HEART MUSCLE CELL; HEMODYNAMICS; HUMAN; HYPERTENSION; MITOGENESIS; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; ANIMAL; ANTIBODY SPECIFICITY; CONGESTIVE HEART FAILURE; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSGENIC ANIMAL; VASCULAR RESISTANCE;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; HEART; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; ORGAN SPECIFICITY; RATS; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM; VASCULAR RESISTANCE; VENTRICULAR REMODELING;

EID: 0036852848     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2002.2075     Document Type: Conference Paper

References (106)

1. Frohlich ED. Risk mechanisms in hypertensive heart disease. Hypertension 1999; 34: 782-789.
2. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med 1996: 156: 1789-1796.
3. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fouad-Tarazi F, Horan MJ, Marcus M, Massie B, Pffefer MA, Re RN, Roccella EJ, Savage Shub C. The heart in hypertension. N Engl J Med 1992; 327: 998-1008.
4. Frohlich ED, Re R. Pathophysiology of systemic arterial hypertension. In: Schlant RC, Alexander RW. O'Rourke RA, Robert R, Sonnenblick EH (eds) Hurst's The Heart 1998. New York: McGraw-Hill Inc: 1635-1650.
5. Susie D, Frohlich ED. Left ventricular hypertrophy: A pathophysiological and molecular biological perspective. Hypertens Res 1993: 16: 163-177.
6. Kannel WB, Dawber TR, Kagan A, Revorskie N, Sacks J. Factors of risk in the development of coronary heart disease: Six year follow up experience: The Framinghem Study. Ann Intern Med 1961; 55: 33-56.
7. Re R. The clinical implication of tissue renin angiotensin system. Curr Opp Cardiol 2001; 6: 317-327.
8. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996: 9: 277-284.
9. Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension 2001; 38: 1246-1249.
10. Braun-Menedez E, Page IH. Suggested revision of nomenclature: Angiotensin. Science 1958: 127: 242.
11. Dostal DE, Rothblum KN, Chernin MI, Cooper GR, Baker KM. Intracardiac detection of angiotensinogen and renin: A localized renin-angiotensin system in neonatal rat heart. Am J Physiol 1992, 263: C838-C850.
12. Zhang X, Dostal DE, Reiss K, Cheng W, Kajstura J, Li P. Huang H. Sonneblick EH. Meggs LG, Baker KM, Anversa P. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes. Am J Physiol 1995: 269: H1791-H1802.
13. Endo-Mochizuki Y, Mochizuki N, Sawa H. Takada A, Okamoto H, Kawaguchi H, Nagashima K, Kitabatake A. Expression of renin and angiotensin-converting enzyme in human hearts. Heart Vessels 1995: 10: 285-293.
14. Barluchhi L, Leri A, Dostal DE, Fiordaliso F, Tada H, Hintze TH, Kajtsura J, Nadal-Giard B, Anversa P. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 2001: 88: 298-304.
15. Sun Y, Zhang J, Zhang JQ, Weber KT. Renin expression at sites of repair in the infracted rat heart. J Mol Cell Cardiol 2001; 33: 995-1003.
16. van Kesteren CA, Saris JJ, Dekkers DH, Lamers JM, Saxena PR, Schalekamp MA. Danser AHI. Cultured neonatal cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: Evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II. Cardiovasc Res 1999: 43: 148-156.
17. Heller LJ, Opsahl JA, Wernsing SE. Saxena R, Katz SA. Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy. Am J Physiol 1998; 274: R849-R856.
18. Von Lutterotti N, Catanzaro DF, Sealer JE, Laragh JH. Renin is not synthesized by cardiac and extra renal vascular tissues. A review of experimental evidence. Circulation 1994; 89: 458-470.
19. van Kesteren CA, Danser AH, Derkx FH, Dekkers DH, Lamers JM, Saxena PR. Schalekamp MA. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension 1997: 30: 1389-1396.
20. Admiraal PJ, van Kesteren CA, Danser AH, Derkx FH, Sluiter W, Schalekamp MA. Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens 1999; 17: 621-629.
21. Sawa H, Tokuchi F, Mochizuki N, Endo Y, Furuta Y. Shinohara T, Takada A, Kawaguchi H, Yasuda H, Nagashima K. Expression of the angiotensinoge gene and localization of its protein in the human heart. Circulation 1992: 86: 138-146.
22. Lee YA, Liang CS, Lee MA, Lindpaintner K. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: A comprehensive study of all its components in the dog. Proc Natl Acad Sci USA 1996: 93: 11035-11040.
23. Shyu KG, Chen JJ, Shih NL, Chang H, Wang DL, Lien WP, Liew CC. Angiotensinogen gene expression is induced by cyclical mechanical stretch in cultured rat cardiomyocytes. Biochem Biophys Res Commun 1995; 211: 241-248.
24. Sadoshima J. Xu Y. Slayter HS. Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984.
25. Dostal DE. Rothblum KN, Baker KM. An improved method for absolute quantification of mRNA using multiplex polymerase chain reaction: Determination of renin and angiotensinogen mRNA levels in various tissues. Anal Biochem 1994: 223: 239-250.
26. Dostal DE. Booz GW. Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid, and beta-adrenergic stimulation. Basic Res Cardiol 2000; 95: 485-490.
27. Kawaguchi H. Kitabatake A. Altered signal transduction system in hypertrophied myocardium: Angiotensin II stimulates collagen synthesis in hypertrophied hearts. J Card Fail 1996; 2 (Suppl 4): S13-S19.
28. de Lannoy LM, Danser AH, van Kats JP. Schoemaker RG, Saxena PR. Schalekamp MA. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart: Local production of angiotensin I. Hypetension 1997; 29: 1240-1251.
29. Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S, Danilov S. Unger T. Cellular distribution of angiotensin-converted enzyme after myocardial infarction. Hypertension 1995; 25: 219-226.
30. Hokimoto S, Yasue H, Fujimoto K. Yamamoto H, Nakao K, Kaikita K, Sakata R, Miyamoto E. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996; 94: 1513-1518.
31. Schunkert H, Dzau VJ, Tang SS, Hirsch AT. Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990; 86: 1913-1920.
32. Iwai N. Shimoike H. Kinoshita M. Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 1995; 92: 2690-2696.
33. Pieruzzi F, Abassi ZA, Keiser HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995; 92: 3105-3112.
34. Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM. Cardiac renin and angiotensins: Uptake from plasma versus in situ synthesis. Hypertension 1994: 24: 37-48.
35. Neri Serneri GG, Boddi M, Coppo M. Chechi T, Zarone N, Moira M. Poggesi L. Margheri M, Simonetti I. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 1996: 94: 1886-1893.
36. Dostal DE, Rothblum KN. Conrad KM, Cooper GR, Baker KM. Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol 1992; 263: C851-C863.
37. Miyata S. Haneda T. Osaki J. Kikuchi K. Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells. Eur J Pharmacol 1996; 307: 81-88.
38. Fischer TA. Ungureanu-Longrois D. Singh K. de Zengotita J. DeUgarte D. Alali A. Gadbut AP. Lee MA, Balligand JL. Kifor I, Smith TW, Kelly RA. Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells. Am J Physiol 1997: 272: H958-H968.
39. Saris J. van den Eijnden M. Lamers J, Saxena P. Schalekamp M. Danser AH. Prorenin-induced myocyte proliferation. No role for intracellular angiotensin II. Hypertension 2002: 39: 573-577.
40. Hackenthal E. Hackenthal R. Hilgenfeldt U. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes. Biochem Biophtds Acta 1978: 522: 574-588.
41. Katwa LC, Campbell SC, Tyagi SC. Lee SJ. Cicila GT. Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997: 29: 1375-1386.
42. Balcells E, Meng QC, Johnson WH Jr. Oparil S, Dell'I Talia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am J Physiol 1997: 273: H1769-1774.
43. Inagami T. Molecular biology and signaling of angiotensin receptors: An overview. J Am Soc Nephrol 1999; 10 (Suppl 11): S2-S7.
44. Dzau VJ, Sasamura H. Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications. J Hypertens 1993; 11 (Suppl 3): S13-S18.
45. Shanmugam S. Corvol P. Gase JM. Angiotensin II type-2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Hypertension 1996; 28: 91-97.
46. Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res 1992: 11: 1482-1489.
47. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S. Kijima K. Maruyama K. Masaki H, Tsutumi I, Shibazaki Y. Iwasaka T, Inada M. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrilar collagen metabolism. Circulation 1997; 96: 3954-3962.
48. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of the angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992; 20: 737-745.
49. Lopez JJ, Lorell BH, Ingelfinger Jr, Weinberg EO. Schunkert H, Diamant D. Tang SS. Distribution and function of cardiac AT1 and AT2 receptors subtypes in hypertrophied rat hearts. Am J Physiol 1994: 267: H844-H852.
50. Nakajima M. Hutchinson HG. Fujinaga M, Hayashida W. Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci 1995: 92: 10663-10667.
51. Stoll M, Steckelings UM, Paul M, Bottari SP. Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995: 95: 651-657.
52. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35: 1074-1077.
53. Fu ML. Schulze W. Wallukat G. Elies R. Eftekhari P, Hjalmarson A, Hoebeke J. Immunochemical localization of angiotensin II receptor (AT1) in the heart with anti-peptide antibodies showing a positive chronotropic effect. Receptors Channels 1998: 6: 99-111.
54. Anderson KM, Murahashi T, Dostal DE. Peach MJ. Morphological and biochemical analysis of angiotensin II internalization in cultured rat aortic smooth muscle cells. Am J Physiol 1993; 264: C179-C188.
55. Re RN. The nature of intracrine peptide hormone action. Hypertension 1999: 34: 534-528.
56. Delcayre C. Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000; 57: 1346-1351.
57. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77: I4-I13.
58. Dzau VJ. Re RN. Evidence for the existence of renin in the heart. Circulation 1987: 75: I134-I136.
59. Unger T, Ganten D, Lang RE, Scholkens BA. Persistent tissue converting enzyme inhibition following chronic treatment with HOE498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1985; 7: 36-41.
60. Lintz W, Schaper J, Wiemer G, Albus U. Scholkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: A one year study in rats. Br J Pharmacol 1992: 107: 970-975.
61. Diez J, Panizo A, Hernandez M, Vega F. Sola I, Fortuno MA. Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 1997; 30: 1029-1034.
62. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Cir Res 1993: 73: 439-447.
63. Campbell DJ, Duncan A-M, Kladis A, Harrap SB. Angiotensin peptides in spontaneously hypertensive and notmotenive Donryu rats. Hypertension 1995: 25: 928-934.
64. Nakamura Y, Nakamura K, Nakamura K. Difference in response of vascular angiotensin converting enzyme activity to cilazapril in SHR. Clin Exp Hypertens 1987; 9: 351-355.
65. Unger T. Gohlke P, Paul M, Rettig R. Tissue renin-angiotensin system: Facts or fiction? J Cardiovasc Pharmacol 1991: 18 (Suppl 2): S20-S25.
66. Brilla CG. Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991: 69: 107-115.
67. Susic D, Varagic J, Frohlich ED. Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens 1999: 17: 1209-1215.
68. Varagic J, Susic D, Frohlich ED. Coronary hemodynamic and ventricular responses to AT1 receptor inhibition in SHR: Interaction with AT2 receptors. Hypertension 2001: 37: 1399-1403.
69. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
70. Schwartzkopff B. Brehem M. Mundhenke M. Strauer B. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000: 36: 220-225.
71. Nunez E. Hosoya K, Susic D, Frohlich ED. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997: 29: 519-524.
72. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995: 47: 25-49.
73. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increase aortic GMP in SHRSP by kinin-dependent mechanisms. Hypertension 1998: 31: 349-355.
74. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller-Brunotte R, Nystrom F, Ohman KP, Osbakken MD, Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001: 19: 1167-1176.
75. Black MJ, Bertram JF, Johnston CI. Cardiac growth during high and low dose perindopril treatment in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1996: 23: 605-607.
76. Kaneko K, Susic D, Nunez E, Frohlich ED. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Med Sci 1997; 314: 21-27.
77. Kaneko K, Susic D, Nunez E, Frohlich ED. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 1996; 14: 645-653.
78. Ando K, Frohlich ED, Chien Y, Pegram BL. Effects of quinaprii on systemic and regional hemodynamics and cardiac mass in spontaneously hypertensive and Wistar-Kyoto rats. J Vasc Med Biol 1991: 3: 117-123.
79. Varagic J, Susic D, Frohlich ED. Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects. J Cardiovasc Pharmacol Therapeut 2001; 6: 57-63.
80. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000: 15: 264-272.
81. Brilla CG, Janicki JS, Weber KT. Advanced hypertensive disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996: 28: 269-275.
82. Phillips RA, Diamond JA. Diastolic function in hypertension. Curr Cardiol Rep 2001; 3: 485-497.
83. Pahor M, Bernabei R, Sgadari A, Gambassi G Jr, Lo Giudice P, Pacifici L, Ramacci MT, Lagrasta C. Olivetti G, Carbonin P. Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension 1991; 18: 148-157.
84. Narayan S, Janicki JS, Shroff SG, Pick R, Weber KT. Myocardial collagen and mechanics after preventing hypertrophy in hypertensive rats. Am J Hypertens 1989: 2: 675-682.
85. Susic D, Nunez E, Hosoya K. Frohlich ED. Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens 1998; 16: 231-237.
86. Villari B, Vassalli G, Schneider J, Chiariello M, Hess O. Age dependency of left ventricular diastolic function in pressure overload hypertrophy. J Am Coll Cardiol 1997: 29: 181-186.
87. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 1996: 154: 171-178.
88. Weber KT. The what, why and how of hypertensive heart disease. J Hum Hypertens 1994; 8: 665-675.
89. Brilla CG. Matsubara LS, Weber KT. Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Moll Cell Cardiol 1993: 25: 563-575.
90. Yu HC, Burrell LM, Black MJ, Wu LL. Dilley RJ. Cooper ME, Johnston CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998: 98: 2621-2628.
91. Kreutz R. Fernandez-Alfonso MS, Liu Y, Ganten D, Paul M. Induction of cardiac angiotensin I-converting enzyme with dietary NaCl-loading in genetically hypertensive and normotensive rats. J Mol Med 1995; 73: 243-248.
92. Mazzolai L. Pedrazzini T. Nicoud F. Gabbiani G. Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35: 985-991.
93. Mazzolai L, Nussberger J, Aubert JF, Brunner DB. Gabbiani G, Brunnet HR. Pedrazzini T. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 1998; 31: 1324-1330.
94. Lee MA, Bohm M, Paul M, Bader M. Ganten U. Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996: 270: E919-E929.
95. 2+ handling in hypertensive transgenic rats over-expressing the Ren2 gene. J Hypertens 2001; 19: 1465-1472.
96. Kannel WB, Ho K. Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994: 72: S3-S9.
97. Garg R. Packer M. Pitt B, Yusuf S. Heart failure in the 1990s: Evolutiuon of a major public health problem in preventive medicine. J Am Coll Cardiol 1993: 22: 3A-8A.
98. Kitzman DW. Heart failure with normal systolic function. Clin Geriatr Med 2000; 16: 489-511.
99. Susic D, Varagic J. Erohlich ED. Isolated systolic hypertension in elderly WKY is reversed with L-arginine and ACE inhibition. Hypertension 2001: 38: 1422-1426.
100. Serneri GGN, Boddi M. Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polodori G, Toscano T, Maccherini M. Modesti PA. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001: 88: 961-968.
101. Diez J, Laviades C. Mayor G. Gil MJ, Monreal I. Iincreased serum concentration of procollagen peptides in essential hypertension: Relation to cardiac alterations. Circulation 1995: 91: 1450-1456.
102. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 1996; 27: 1031-1038.
103. Strauer BE. Schwartzkopf B. Objectives of high blood pressure treatment: Left ventricular hypertrophy, diastolic function, and coronary reserve. Am J Hypertens 1998: 11: 879-881.
104. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Ubago JLM, Diez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001: 104: 286-291.
105. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricuiar ejection fractions and congestive heart failure. N Engl J Med 1991: 325: 293-301.
106. Pfeffer MA. Braunwald E. Moye LA. Basta L, Brown EJ Jr. Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-677.